Trial Information
A Prospective, Randomized Blinded Multicenter, Parallel Study Comparing Transdermal, Continuous Oxygen Delivery to Moist Wound Therapy (MWT) in the treatment of Diabetic Foot Ulcers

Study Population:
Male and female patients 20-90 years of age with type 1 or type 2 diabetes mellitus with non-healing, full-thickness, University of Texas Classification of Diabetic Foot Ulcers Class IA diabetic foot ulcers of at least 4 weeks duration, but not greater than 52 weeks, measuring 1 -10 cm² in area

Qualifying subjects will be randomized with a 1:1 ratio (i.e., Active arm: Control arm) with two stratification factors. The stratification factors are used to ensure a balanced distribution of subjects with characteristics important to healing in the Active and Control arms. The active arm is a currently FDA Approved device called EpiFlo, small, silent, disposable, oxygen concentrator used in the treatment of chronic and acute wounds. The control arm will receive sham units with a look and feel of active units, but will not provide oxygen.

Goal:
The primary objective of this study is to compare number of wounds closed on or at week 12 between subjects randomized to receive EPIFLO or MWT.

Lead Principal Investigator:
- Vickie R Driver MS DPM FACFAS (Lead Principal Investigator)

US Investigators:
Dr. Bryan Caldwell: Ohio College of Podiatric Medicine, Independence, OH
Dr. Frederick Kruger: Center for Clinical Research, Fresno CA
Dr. Matthew Regulski: Ocean County Foot and Ankle Surgical Associates: Toms River, NJ
Dr. James Canterbury: Various offices, Alliance, Navarre and Hartville, OH
Dr. Geoffrey Habershaw: Boston Medical Center, Boston, MA

Canadian Investigators
Dr. R Gary Sibbald: Debary Dermatology, Mississagua, Ontario Canada
Dr. Perry Mayer: The Mayer Institute, Hamilton, Ontario Canada

Sponsors:
Neogenix, D/B/A Ogenix, 588 Pleasant St Unit 2, Norwood, MA 02062